Replek AD (XMAE:REPL) YoY EBITDA Growth : -44.85% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Replek AD YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Replek AD's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -44.85%.

Replek AD's EBITDA per Share for the three months ended in Mar. 2025 was MKD222.44.

Replek AD YoY EBITDA Growth Historical Data

The historical data trend for Replek AD's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD YoY EBITDA Growth Chart

Replek AD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

27.26

-13.85

0.34

128.41

6.66

Replek AD Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															159.37	-45.56	-73.22	5.76	-44.85

Replek AD YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Replek AD's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(1619.294	-	1518.119)	/	\| 1518.119 \|
=	6.66 %

Replek AD's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(222.444	-	403.34)	/	\| 403.34 \|
=	-44.85 %

Replek AD YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Replek AD's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Replek AD Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kozle 188, Skopje, MKD

Website

https://www.replek.mk

Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.